Cervical cancer is tightly linked to persistent high-risk HPV infection across squamous and adenocarcinoma subtypes. Key biology includes HPV E6/E7, p16 (surrogate readout), cell-cycle/DDR programs, PD-L1, and angiogenesis. We provide antibodies and tools around HPV, p16, Ki-67, PD-L1, VEGF, plus platinum/taxane/checkpoint research probes for screening translation, CRT sensitization, and IO mechanisms.
Focus areas: HPV oncogenesis & p16, chemoradiation, anti-angiogenesis + IO combos, relapse clonal evolution
Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.
| Compound | Targets / pathways | Experimental notes |
|---|---|---|
| Cisplatin | DNA crosslinking (platinum) | Common CRT/advanced-line comparator; mind nephrotoxicity/hydration protocols. |
| Carboplatin | DNA crosslinking (platinum) | Myelosuppression & AUC dosing—align with ethics and species PK. |
| Paclitaxel | Microtubule stabilization | Taxane–platinum readouts; separate mitotic catastrophe vs apoptosis. |
| Pembrolizumab | PD-1 | Recurrent/metastatic IO context; pair PD-L1 CPS & MSI where applicable. |
| Topotecan | Topoisomerase I | Second-line/recurrent studies; mind myelosuppression/schedules. |
| Bevacizumab | VEGF-A | Anti-VEGF + chemo readouts; monitor wound healing/BP in vivo. |
| Cetuximab | EGFR (ADCC context) | Pair with EGFR expression & MAPK readouts; manage dermatologic toxicity. |